Endocrine Abstracts

Objectives: Finding novel tumor markers capable to recognize aggressive papillary thyroid carcinoma (PTC) forms are of great importance. We evaluated hsa-microRNA-204-3p (miR-204-3p) for differential diagnosis of thyroid tumors and assessed its prognostic usefulness.Methods: MiR-204-3p levels were determined in 77 PTC cases of diverse histological variants, 12 cases of follicular thyroid adenoma (FTA), and 89 matched nonmalignant thyroid epithelial tissu...

Oxidative stress (OS) can have an impact both in the pathogenesis and in the progression of TC, as it has been shown to induce oncogenes and inhibit tumor suppressors. The main source of cellular ROS is represented by NADPH oxidases (NOXs). Aims of the study were to investigate the NOX-derived OS in TC samples, benign nodules and corresponding normal tissues, and to correlate the level of OS with histological classification, genetic profile and clinical and prognostic features...

Objective: Improved molecular testing for common somatic mutations and the identification of mRNA and microRNA expression classifiers are promising approaches for the diagnosis of thyroid nodules. However, there is a need to improve the diagnostic accuracy of such tests in identifying thyroid cancer. Recent findings have revealed a crucial role of lncRNAs in gene modulation. Thus, we aimed to evaluate the diagnostic value of selected lncRNAs from The Atlas of Noncoding RNAs in...

Background: Medullary thyroid carcinoma (MTC) can result from an inherited predisposition related to variants in the RET gene. The insTTCTdelG variant in codon 666 has been previously associated with MTC in one family, but larger studies are not available. We aim to describe biochemical and clinical characteristics associated with this genetic variant in sixteen Belgian families.Methods: Retrospective study of sixteen families in Belgium, evalua...

Papillary thyroid carcinoma (PTC) is the most frequent histological subtype of thyroid cancers and BRAFV600E genetic alteration is found in 60% of this endocrine cancer. BRAFV600E tumors are associated with poor prognosis resistance to radioiodine therapy and tumor progression. Histological follow-up by anatomo-pathologists reveals that 2/3 of surgically-removed thyroid do not present malignant lesions. Continued fundamental research into the molecular me...

Thyroid cancer (TC) is the most common endocrine tumor and its incidence has increased faster than in any other malignancy. Although TCs are usually well differentiated, disease recurrence or persistence is high, because of local and distant metastasis and therapeutic resistance. As in other cancer types, despite the promising results obtained in pre-clinical studies, the efficacy of Targeted Therapy is highly variable and therapy resistance is not uncommon. This may be due to...

Objective: Thyroid nodules are the most common thyroid disease and preoperative differentiation of benign and malignant lesions is an important diagnostic purpose. In about 1/3 cases FRA and cytological examination shows indeterminate diagnosis. Deregulation of miRNA expression has been described in a variety of tumors, including thyroid cancer. The aim of our study is to evaluate the association between miRNAs expression and risk of thyroid cancer in patients with thyroid nod...

Objectives: Variants in the EIF1AX gene have been reported in malignant as well as benign thyroid nodules and their clinical significance is still unclear due to their low prevalence. The aim of this study was to identify EIF1AX variants in a large cohort of different types of thyroid nodules and to correlate them with clinical and pathological data.Methods: The study consisted of 904 thyroid nodule samples. The cohort included 577 papi...

Objectives: MCL-1 and PD-L1 proteins are related to carcinogenesis mechanisms in differentiated thyroid carcinoma (DTC). Tumor antigens stimulate the expression of PD-1 in immune cells, which binds to PD-L1 of tumor cells, inducing immune escape from the tumor. MCL-1, an anti-apoptotic member of the BCL-2 family and has a high oncogenic potential. The relationship of these markers with prognosis in DTC remains unknown. We aim to evaluate the clinical utility of immunohistochem...

Objectives: BRAFV600E mutation is present in 50% of aggressive papillary thyroid carcinoma(PTC). TERT promoter (pTERT) mutations (C228T, C250T) are related to cancer growth and reduced overall- and disease-free survivals in differentiated thyroid carcinomas(DTC). We report a patient with an extremely aggressive PTC presenting in the primary lesion two pTERT mutations (C228T and C250T), and absence of BRAFV600E.<p class="abstext"...